Literature DB >> 26481278

Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.

Yunge Zhao1, Jacob R Gillen1, Akshaya K Meher1, Jordan A Burns1, Irving L Kron1, Christine L Lau2.   

Abstract

OBJECTIVE: B lymphocytes are generally considered to be activators of the immune response; however, recent findings have shown that a subtype of B lymphocytes, regulatory B lymphocytes, play a role in attenuating the immune response. Bronchiolitis obliterans remains the major limitation to modern-day lung transplantation. The role of regulatory B lymphocytes in bronchiolitis obliterans has not been elucidated. We hypothesized that regulatory B lymphocytes play a role in the attenuation of bronchiolitis obliterans.
METHODS: We performed a standard heterotopic tracheal transplant model. Tracheas from Balb/c mice were transplanted into C57BL/6 recipients. Rapamycin treatment and dimethyl sulfoxide control groups were each treated for the first 14 days after the transplant. Tracheas were collected on days 7, 14, and 28 post-transplantation. Luminal obliteration was evaluated by hematoxylin-eosin staining and Picrosirius red staining. Immune cell infiltration and characteristics, and secretion of interleukin-10 and transforming growth factor-β1 were accessed by immunohistochemistry. Cytokines and transforming growth factor-β1 were measured using the Luminex assay (Bio-Rad, Hercules, Calif).
RESULTS: The results revealed that intraperitoneal injection of rapamycin for 14 days after tracheal transplantation significantly reduced luminal obliteration on day 28 when compared with the dimethyl sulfoxide control group (97.78% ± 3.63% vs 3.02% ± 2.14%, P < .001). Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-β1(+)) cells when compared with dimethyl sulfoxide controls. Rapamycin treatment inhibited interleukin-1β, 6, 13, and 17 on days 7 and 14. Rapamycin also greatly increased interleukin-10 and transforming growth factor-β1 production in B cells and regulatory T lymphocytes infiltration on day 28.
CONCLUSIONS: Mammalian target of rapamycin inhibition decreases the development of bronchiolitis obliterans via inhibition of proinflammatory cytokines and increasing regulatory B lymphocytes cell infiltration, which subsequently produces anti-inflammatory cytokines and upregulates regulatory T lymphocyte cells. Published by Elsevier Inc.

Entities:  

Keywords:  FoxP3β regulatory T cells; bronchiolitis obliterans; mouse heterotopic tracheal transplant; rapamycin; regulatory B lymphocytes

Mesh:

Substances:

Year:  2015        PMID: 26481278      PMCID: PMC4728002          DOI: 10.1016/j.jtcvs.2015.08.116

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  44 in total

1.  Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

Authors:  David J DiLillo; Yasuhito Hamaguchi; Yoshihiro Ueda; Kaiyong Yang; Junji Uchida; Karen M Haas; Garnett Kelsoe; Thomas F Tedder
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 2.  B lymphocytes: how they develop and function.

Authors:  Tucker W LeBien; Thomas F Tedder
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

Review 3.  Cytokine-producing B lymphocytes-key regulators of immunity.

Authors:  Frances E Lund
Journal:  Curr Opin Immunol       Date:  2008-04-15       Impact factor: 7.486

4.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 5.  The 'short' history of regulatory B cells.

Authors:  Claudia Mauri; Michael R Ehrenstein
Journal:  Trends Immunol       Date:  2007-12-03       Impact factor: 16.687

6.  [The role of transforming growth factor-beta1/Smad3 signaling in bronchiolitis obliterans following lung transplantation].

Authors:  Hong-xu Liu; Yu Li; Cheng-hai Zhao; Yang Liu; Qi-gang Zhang; Wei Cong; Xin-gang Lan; Shun Xu; Li-bo Han; Lin Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-08-07

7.  A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Karen M Haas; Jonathan C Poe; Manabu Fujimoto; Thomas F Tedder
Journal:  Immunity       Date:  2008-05       Impact factor: 31.745

Review 8.  Not always the bad guys: B cells as regulators of autoimmune pathology.

Authors:  Simon Fillatreau; David Gray; Stephen M Anderton
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

9.  A mouse model of orthotopic vascularized aerated lung transplantation.

Authors:  M Okazaki; A S Krupnick; C G Kornfeld; J M Lai; J H Ritter; S B Richardson; H J Huang; N A Das; G A Patterson; A E Gelman; D Kreisel
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

Review 10.  Regulatory B cells as inhibitors of immune responses and inflammation.

Authors:  Jean-David Bouaziz; Koichi Yanaba; Thomas F Tedder
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

View more
  8 in total

1.  Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.

Authors:  Takashi K Kishimoto; Joseph D Ferrari; Robert A LaMothe; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; Victor Chan; Erica Browning; Aditi Chalishazar; William Kuhlman; Fen-Ni Fu; Nelly Viseux; David H Altreuter; Lloyd Johnston; Roberto A Maldonado
Journal:  Nat Nanotechnol       Date:  2016-08-01       Impact factor: 39.213

2.  SOCS3 overexpression in T cells ameliorates chronic airway obstruction in a murine heterotopic tracheal transplantation model.

Authors:  Kumi Mesaki; Masaomi Yamane; Seiichiro Sugimoto; Masayoshi Fujisawa; Teizo Yoshimura; Takeshi Kurosaki; Shinji Otani; Shinichiro Miyoshi; Takahiro Oto; Akihiro Matsukawa; Shinichi Toyooka
Journal:  Surg Today       Date:  2019-01-07       Impact factor: 2.549

3.  Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.

Authors:  Daniel Fantus; Helong Dai; Yoshihiro Ono; Alicia Watson; Shinichiro Yokota; Kanishka Mohib; Osamu Yoshida; Mark A Ross; Simon C Watkins; Bala Ramaswami; Anna Valusjkikh; David M Rothstein; Angus W Thomson
Journal:  Transplantation       Date:  2017-12       Impact factor: 4.939

4.  Importance of B cells to development of regulatory T cells and prolongation of tissue allograft survival in recipients receiving autologous bone marrow transplantation.

Authors:  Reginald M Gorczynski; Kaveh Farrokhi; Christopher Gorczynski; Hassan Sadozai; Fang Zhu; Ismat Khatri
Journal:  Immunology       Date:  2018-02-20       Impact factor: 7.397

5.  The proportion of CD19+CD24hiCD27+ regulatory B cells predicts the occurrence of acute allograft rejection in liver transplantation.

Authors:  Haoming Zhou; Feng Zhan; Hui Zhang; Jian Gu; Xiaoxin Mu; Ji Gao; Jianhua Rao; Guwei Ji; Xuhao Ni; Ling Lu; Yongxiang Xia
Journal:  Ann Transl Med       Date:  2019-09

6.  LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats.

Authors:  Zheng-Liang Tu; Zhen-Yu Zhou; Hai-Chao Xu; Jin-Lin Cao; Peng Ye; Lu-Ming Wang; Wang Lv; Jian Hu
Journal:  J Cardiothorac Surg       Date:  2017-05-25       Impact factor: 1.637

7.  Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.

Authors:  Marniker Wijesinha; Jon Mark Hirshon; Michael Terrin; Laurence Magder; Clayton Brown; Kristen Stafford; Aldo Iacono
Journal:  JAMA Netw Open       Date:  2019-08-02

Review 8.  B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications.

Authors:  Birte Ohm; Wolfgang Jungraithmayr
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.